Cipla USA acquires anti-infective Zemdri from Achaogen Inc

Drug firm Cipla has said its arm Cipla USA Inc has acquired prescription drug Zemdri, used for the treatment of complicated urinary tract infections, from Achaogen Inc. Cipla USA has acquired worldwide rights of Zemdri, excluding Greater China, with its allied assets and limited liabilities, Cipla said in a late night regulatory filing on Wednesday. "The acquisition of Zemdri deepens our pipeline of specialty products in the US in our identified focus areas of central nervous system, lung delivery of medicines, and institutionally administered products," Cipla MD and Global CEO Umang Vohra said. Zemdri is a once-daily novel intravenous (IV) aminoglycoside for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, in adults who are unresponsive to currently available treatment options, Cipla said.

Upload Company Info



Chemxpert Demo Video


Dataset Sample


Chemical Name

Synonyms

Molecular Formula

Molecular Weight


To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Innovator

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Market Status

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Indication

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Therapeutic Segment

To Access this information please pay by using "Pay & Download" button.

Pay & Download

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Thank you for your enquiry

Your product will be updated soon in our database


Submit Your Query



Select Any Option



Page loaded in 0.001184 seconds